

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 16, 2016**

The quarterly meeting of the ODM DUR Board was called to order at 12:01 PM in room South A and B on the 31st Floor of the Riffe Center, 77 S. High Street, Columbus, Ohio. Michael Farrell, MD, presided. The following Board members were present:

David Brookover, RPh
Michael Farrell, MD, Chair
Robert Kubasak, RPh
Lenard Presutti, DO
Donald Sullivan, RPh

Also present from ODM were: Michael Howcroft, RPh, Margaret Scott, RPh, DUR Administrator; Patti Nussle, RPh, and PharmD candidate Julie Valdes. Pam Heaton, RPh, PhD represented the University Of Cincinnati. Chad Bissell, PharmD, Jill RK Griffith, PharmD and Robyn Satterfield, PharmD were in attendance from Goold Health Systems (GHS). Approximately 15 observers were present, most representatives of pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The November 17th, 2015, DUR Board minutes were approved with one correction. (1st R. Kubasak, 2nd D. Brookover).

Conflict of Interest Statement

The DUR Board members signed the annual Conflict of Interest Statement.

DUR Committee Report:

M. Scott stated that GHS has been presenting information to the DUR Committee in advance of a late spring 2016 new pharmacy claims processing system implementation. GHS is educating the Committee about the prospective DUR capabilities of the new system, and suggesting edits for ODM to consider.

Health Plan Policy:

M. Scott updated the Board on The Governor's Cabinet Opiate Action Team. The Ohio acute pain prescribing guideline titled the *Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments* was released and is being implemented. The State is monitoring. Naloxone is now dispensable by pharmacists in consult agreement with physicians. Much discussion ensued.

Unfinished Business:

GHS clinical account manager R. Satterfield presented a report of Drug-Drug Interactions for Board consideration. Discussion ensued regarding appropriate drug-drug interactions that should message in the new claims processing system and those that should deny at the point of sale and require the pharmacist to take action. The list of interactions is attached. The system will deny claims with the listed interactions if

the prescribers are different, with the interaction of sulfamethoxazole/trimethoprim with anticoagulants set to deny even if they are from the same prescriber. The pharmacist can override the denial using standard intervention and outcome codes. The Board discussed the balance needed between providing clinically meaningful information and the possibility of “alert fatigue.”

New Business:

Elections for Chair and Vice Chair were held. L. Presutti was elected Chair and D. Sullivan elected Vice Chair. Dr. J. Layne Moore recently resigned and the Board is vacant one pharmacist and physician. M. Scott is speaking with professional organizations to find replacements. Discussion ensued.

Announcements:

The Board decided on the meeting schedule for the remainder of 2016:

- May 17
- September 20
- November 15

Adjournment:

Dr. Farrell adjourned the meeting at 12:25 PM.

Respectfully submitted:

Margaret Scott, RPh, DUR Administrator